The Technical Analyst
Intercept Pharmaceuticals [ICPT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Intercept Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.21% $19.00
America/New_York / 7 nov 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 794.69 mill |
| EPS: | -1.090 |
| P/E: | -17.43 |
| Earnings Date: | Nov 05, 2023 |
| SharesOutstanding: | 41.83 mill |
| Avg Daily Volume: | 2.05 mill |
| RATING 2023-11-14 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Buy | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -17.43 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.97x |
| Company: PE -17.43 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 18.59 - 19.41 ( +/- 2.16%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-11-08 | Akkaraju Srinivas | Sell | 640 688 | Common Stock |
| 2023-11-08 | Akkaraju Srinivas | Sell | 8 111 | Common Stock |
| 2023-11-08 | Akkaraju Srinivas | Sell | 12 089 | Option to Purchase Common Stock |
| 2023-11-08 | Akkaraju Srinivas | Sell | 12 790 | Option to Purchase Common Stock |
| 2023-11-08 | Akkaraju Srinivas | Sell | 12 547 | Option to Purchase Common Stock |
| INSIDER POWER |
|---|
| -100.00 |
| Last 100 transactions |
| Buy: 0 | Sell: 1 646 020 |
Forecast:
01:40 - $19.13
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $19.00 (0.21% ) |
| Volume | 3.91 mill |
| Avg. Vol. | 2.05 mill |
| % of Avg. Vol | 190.11 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ICPT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ICPT
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
Latest Press Releases
2024-02-29 08:30:00 - Press Release
Intercept Announces Fda Acceptance Of Supplemental New Drug Application For Ocaliva® (obeticholic Acid) For The Treatment Of Pbc
Morristown, n.j., feb. 29, 2024 (globe newswire) -- intercept pharmaceuticals, inc., a biopharmaceutical company and wholly owned subsidiary of alfasigma s.p.a. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the u.s. food and drug administration (fda) has accepted its supplemental new drug application (snda) for ocaliva for the treatment of individuals with primary biliary cholangitis (pbc). the fda has assigned a prescription drug user fee act (pdufa) target action date of october 15, 2024. in this communication, the agency informed intercept that they are planning to hold an advisory committee meeting to discuss the application.
2023-11-08 09:13:00 - Press Release
Alfasigma Completes Acquisition Of Intercept Pharmaceuticals, Inc.
Bologna, italy and morristown, n.j., nov. 08, 2023 (globe newswire) -- alfasigma s.p.a. (“alfasigma”) and intercept pharmaceuticals, inc. (“intercept”) announced today the completion of the acquisition of intercept by alfasigma through its wholly owned subsidiary interstellar acquisition inc.
2023-11-08 09:12:00 - Press Release
Alfasigma Completes Acquisition Of Intercept Pharmaceuticals, Inc.
Bologna, italy & morristown, n.j.--(business wire)--alfasigma s.p.a. (“alfasigma”) and intercept pharmaceuticals, inc. ( “intercept”) announced today the completion of the acquisition of intercept by alfasigma through its wholly owned subsidiary interstellar acquisition inc. following the completion of alfasigma's successful tender offer to purchase all outstanding shares of common stock of intercept for usd 19.00 per share, net to the seller thereof in cash, without interest, less any applicab.
2023-11-08 02:08:00 - Press Release
Alfasigma S.p.a. Successfully Completes Tender Offer For All Outstanding Shares Of Common Stock Of Intercept Pharmaceuticals, Inc.
Bologna, italy--(business wire)--alfasigma s.p.a. (“alfasigma”) announced today that it has, through its wholly owned subsidiary interstellar acquisition inc. (“interstellar”), successfully completed its tender offer to purchase all outstanding shares of common stock of intercept pharmaceuticals, inc. (nasdaq: icpt) (“intercept”), at a price of usd 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withholding of taxes. the tender offer expired as schedule.
2023-10-16 12:53:00 - Press Release
Intercept Pharmaceuticals Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Intercept Pharmaceuticals, Inc. - Icpt
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of intercept pharmaceuticals, inc. (nasdaqgs: icpt) to alfasigma s.p.a. under the terms of the proposed transaction, shareholders of intercept will receive $19.00 in cash for each share of intercept that they own. ksf is seeking to determine whether this consideration and the process that led to it are adequate,.
Latest News
2023-10-31 11:17:59 - Zacks Investment Research
Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know
Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2023-10-19 07:03:10 - InvestorPlace
Stocks to Sell: 7 Overbought Companies You Ought to Dump Right Now
In rough markets it's important to keep and eye out for overbought stocks. Finding the right timing to buy and sell stocks will always be a sought-after skill by any investor searching for that holy grail.
2023-09-27 06:46:03 - Zacks Investment Research
Intercept (ICPT) Stock Jumps 79.2%: Will It Continue to Soar?
Intercept (ICPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2023-09-26 14:17:26 - The Motley Fool
Why Intercept Pharmaceuticals Stock Is Skyrocketing Today
The stock is exploding following an announcement that it's on track to be acquired. Alfasigma is poised to buy Intercept at a price of $19 per share.
2023-09-26 14:11:35 - InvestorPlace
Why Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?
Amid a rough day on Wall Street, Intercept Pharmaceuticals (NASDAQ: ICPT ) represented a bright spot, with shares swinging up 75% before slightly adding to those gains. Catapulting the biopharmaceutical specialist was the announcement that Italy-based Alfasigma will acquire Intercept, seeking to leverage its lead therapeutic Ocaliva.
2023-09-26 11:42:58 - Proactive Investors
Intercept Pharmaceuticals stock soars on Alfasigma acquisition deal
Intercept Pharmaceuticals (NASDAQ:ICPT) Inc shares surged 79% to $18.64 in late-morning trading on Tuesday after the biopharmaceutical company specializing in rare and serious liver diseases announced that it has agreed to be acquired by Alfasigma SpA, one of Italy's largest pharma companies, for $19 per share in cash, or an 82% premium to Intercept's closing price on September 25, 2023. Intercept's lead medicine is Ocaliva, the only US Food and Drug Administration (FDA) approved second-line treatment for primary biliary cholangitis (PBC), a progressive autoimmune disease affecting the liver, which generated revenue of $152 million during the first half of 2023.
2023-09-26 08:12:00 - Market Watch
Intercept Pharmaceuticals' stock set to soar after Alfasigma buyout deal for an 82% premium
Shares of Intercept Pharmaceuticals Inc. ICPT, -0.38% were set to soar Tuesday, after the biopharmaceutical company announced an agreement to be acquired by Italy's Alfasigma S.p.A in a deal that values Intercept shares at an 82% premium. Intercept's stock has been halted for news until 8:30 a.m.
2023-08-02 11:57:57 - Zacks Investment Research
Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y
Intercept (ICPT) reports a lower net loss and beats on revenues in the second quarter. The company also updates its guidance for its lead drug, Ocaliva.
2023-08-02 11:28:05 - Seeking Alpha
Intercept Pharmaceuticals, Inc. (ICPT) Q2 2023 Earnings Call Transcript
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Nareg Sagherian - Executive Director, Investor Relations Jerry Durso - President and CEO Andrew Saik - Chief Financial Officer Linda Richardson - Chief Commercial Officer Michelle Berrey - President, Research & Development and Chief Medical Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Mayank Mamtani - B. Riley Securities Ed Arce - H.C.
2023-06-26 14:16:34 - Zacks Investment Research
Intercept (ICPT) to Restructure Operations, Cut Workforce
Intercept (ICPT) looks to restructure operations, discontinue all NASH-related investments and reduce its workforce by one-third.